Mean evanescence rates by RBC alloantibody specificity
Blood group system . | General patient groups (%)* . | Sickle cell disease groups (%)* . |
---|---|---|
Duffy | ||
Fya | 17 | 51 |
Fyb | — | 78 |
Kell | ||
K | 32 | 41 |
Jsa | — | 80 |
Kidd | ||
Jka | 49 | — |
Jkb | 54 | 58 |
Lewis | ||
Lea | 48 | — |
Leb | 52 | — |
Lutheran | ||
Lua | 65 | — |
MNS | ||
M | 30 | 38 |
S | 30 | 66 |
P | ||
P1 | 50 | — |
Rh | ||
D | 12 | 36 |
C | 19 | 47 |
c | 27 | 0 |
E | 38 | 41 |
Cw | 61 | — |
V | — | 39 |
Blood group system . | General patient groups (%)* . | Sickle cell disease groups (%)* . |
---|---|---|
Duffy | ||
Fya | 17 | 51 |
Fyb | — | 78 |
Kell | ||
K | 32 | 41 |
Jsa | — | 80 |
Kidd | ||
Jka | 49 | — |
Jkb | 54 | 58 |
Lewis | ||
Lea | 48 | — |
Leb | 52 | — |
Lutheran | ||
Lua | 65 | — |
MNS | ||
M | 30 | 38 |
S | 30 | 66 |
P | ||
P1 | 50 | — |
Rh | ||
D | 12 | 36 |
C | 19 | 47 |
c | 27 | 0 |
E | 38 | 41 |
Cw | 61 | — |
V | — | 39 |
Data were extracted and aggregated from previously published studies, with evanescent antibodies of each specificity available totaled and divided by the overall number of antibodies of that specificity identified. To be included in the above analysis, the overall number of antibodies of a given specificity had to tally ≥5. Dashes indicate that too few antibodies of a given specificity were available for inclusion in the analysis.